Article Corrected

Benedict Á, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. *Pharmacoeconomics* 2010; 28 (3): 185-99

Correction Made

Page 194, column 2, final sentence of the Results section, which previously read:

“By contrast, the cost-effectiveness acceptability curve for the total seizure analysis shows rufinamide to be cost effective in 80% of analyses if society is willing to pay £900 for a 1% increase in the number of successfully treated patients (figure 2b).”

has now been corrected as follows:

“By contrast, the cost-effectiveness acceptability curve for the total seizure analysis shows that above £2150 rufinamide has the highest chance of being cost effective across the treatment comparisons (figure 2b).”

Note

All online versions of this article have been updated to reflect this correction.